Literature DB >> 26308327

Drug Effects and Clinical Investigations for Contrast-Induced Nephropathy After Coronary Angiography or Percutaneous Coronary Intervention in Patients With Diabetes.

Man-Man Zhang1, Qian-Zhou Lv, Xiao-Ye Li.   

Abstract

The aim of the study was to investigate the risk factors of preprocedural laboratory investigations and drug effects to the incidence of contrast-induced nephropathy (CIN) in patients with diabetes who underwent coronary angiography or percutaneous coronary intervention and to assess the short-term safety. We retrospectively studied a total of 568 patients with diabetes who underwent coronary angiography or percutaneous coronary intervention from January, 2013 to January, 2014 in our hospital and compared the baseline clinical characteristics, especially the laboratory investigations and preprocedural drugs of those 2 groups (with CIN group and without CIN group), and half year follow-up. Overall, 53 (9.33%) patients were developed into CIN according to the definition of an increase of 25% from the baseline of serum creatinine concentration, supposing that on the basis of an increase of 44.2 μmol/L, the incidence would be 0.88% (5/568). No significant differences were found between the 2 groups with respect to age, diabetes mellitus duration, operation type, contrast type and volume, left ventricular ejection fraction, and combined diseases including hypertension, myocardial infarction, Arrhythmia, etc. However, patients with CIN tended to be lighter in body weight (P = 0.027) and were more often female [odds ratio (OR) = 2.8, P < 0.01], and also had a higher prevalence with acute coronary syndrome (OR = 5.1, P < 0.01). On the contrary to most studies, the preprocedural serum creatinine in with CIN group in our study was lower than without CIN group (P < 0.001). As for the preprocedural drugs, statins seemed could decrease the incidence of CIN (OR = 0.34, P < 0.05), and the use of diuretics might increase the occurrence of CIN (OR = 2.62, P < 0.05). As regard to the follow-up results, the hospitalization days and expense of with CIN group were significantly longer and higher than the without CIN group, but no significance was found between rehospitalization rate in half year. Preprocedural preventions are essential because there is no effective treatment for CIN our findings could be considered in clinical practice. There are many risk factors for CIN; it is necessary to distinguish the high-risk patients so as to carry out corresponding protection actions.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 26308327     DOI: 10.1097/MJT.0000000000000325

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  4 in total

1.  Diastolic dysfunction predicts the risk of contrast-induced nephropathy and outcome post-emergency percutaneous coronary intervention in AMI patients with preserved ejection fraction.

Authors:  Beibei Han; Yongguang Li; Zhifeng Dong; Qing Wan; Hong Shen; Jingbo Li; Meng Wei; Chengxing Shen
Journal:  Heart Vessels       Date:  2018-04-27       Impact factor: 2.037

2.  Analysis of the risk factors for contrast-induced nephropathy in over-aged patients receiving coronary intervention.

Authors:  Hui-Chao Pan; Xian-Hao Wu; Qian-Li Wan; Bao-Hong Liu And; Xu-Sheng Wu
Journal:  Exp Biol Med (Maywood)       Date:  2018-08

3.  Association of left ventricular ejection fraction with contrast-induced nephropathy and mortality following coronary angiography or intervention in patients with heart failure.

Authors:  Kun Wang; Hua-Long Li; Wei-Jie Bei; Xiao-Sheng Guo; Shi-Qun Chen; Sheikh Mohammed Shariful Islam; Ji-Yan Chen; Yong Liu; Ning Tan
Journal:  Ther Clin Risk Manag       Date:  2017-07-19       Impact factor: 2.423

4.  Impact of Geriatric Nutritional Index in Contrast-Induced Nephropathy Developed in Patients with Non-ST Segment Elevation Myocardial Infarction who Underwent Percutaneous Coronary Intervention.

Authors:  Mehmet Kucukosmanoglu; Arafat Yildirim; Fethi Yavuz; Mustafa Dogdus; Salih Kilic
Journal:  Medeni Med J       Date:  2020-02-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.